Q1 FY 20 Performance Update

We have improved our business performance in last few years... SALES: 2 year CAGR of 5% EBITDA: 2 year CAGR of 16% INR Cr. 15,385 14,081 14,203 3,419 1,973 1,468 1,424 2,414 2,128 2,199 2,549 2,408 31% 4,420 4,598 5,507 36% 18.1% 17.0% 22.2% 45% 6,360 5,982 39% 5,996 FY17 FY18 FY19 NAG India + EM PSAI Others Dr. Reddy's We have well diversified revenue streams between generics and branded generic markets. FY17 FY18 FY19 ■ EBITDA % to Sales EBITDA margins improving due to optimization of cost and growth in emerging markets PROPRIETARY

View entire presentation